ACH 3422

Drug Profile

ACH 3422

Alternative Names: ACH-0143422; ACH-3422

Latest Information Update: 17 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Antivirals; Small molecules; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 19 May 2015 ACH 3422 licensed to Janssen Pharmaceuticals worldwide
  • 05 Mar 2015 Achillion plans the SPARTA doublet regimen trial for Hepatitis C (Combination therapy, Treatment-naive) in New Zealand
  • 05 Mar 2015 Achillion plans the ITHACA triplet regimen trial for Hepatitis C (Combination therapy, Treatment-naive) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top